Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results. J Eur Acad Dermatol Venereol 2025 Apr 03
Severity of almond allergy and diagnostic value of almond extract in adults. J Allergy Clin Immunol Pract 2025 Mar 27
Dupilumab-Associated Ocular Surface Disease in Paediatric Atopic Dermatitis Patients: Results From the BioDay Registry. Clin Exp Allergy 2025 Mar 18
Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitis. Pediatr Allergy Immunol 2025 Feb; 36(2):e70040
Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment. Clin Exp Allergy 2025 Mar; 55(3):260-263
Increasing dosing intervals for biologics in atopic dermatitis-why, who, when and how? J Eur Acad Dermatol Venereol 2025 Jan 22
Exploring Social Health in Patients with Atopic Dermatitis: An Observational, Cross-sectional, Questionnaire Based Study on Social Participation and Emotional Support. Acta Derm Venereol 2025 Jan 08; 105:adv41129
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials. J Am Acad Dermatol 2025 May; 92(5):1024-1031
Improvement in quality of life in patients treated with lebrikizumab monotherapy is mediated by improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis. Clin Exp Dermatol 2024 Dec 16
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels. Allergy 2025 Apr; 80(4):1060-1073
Type 2 Immune-Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients. Clin Exp Allergy 2025 Jan; 55(1):97-99
Assessing Disease Control in Patients with Atopic Dermatitis by Using the Atopic Dermatitis Control Tool in Daily Practice. Dermatology 2024; 240(5-6):732-738
Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis. JAMA Dermatol 2025 Jan 01; 161(1):12-21
Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis. J Am Acad Dermatol 2025 Feb; 92(2):242-251
Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study. Allergy 2025 Feb; 80(2):489-499